Yang J, Rao H Y
Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing 100044, China.
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):175-178. doi: 10.3760/cma.j.issn.1007-3418.2018.03.004.
Hepatitis C is one of the major causes of liver disease worldwide. Chronic hepatitis C can cause liver fibrosis and cirrhosis leading to end-stage liver disease. Antiviral therapy can clear the virus, stop the progress of the disease, thereby reducing the incidence of advanced liver disease. This article aims to discuss the effects and safety of antiviral treatments, including direct- acting antiviral agents, on patients with chronic hepatitis C with fibrosis and compensated and decompensated liver cirrhosis.
丙型肝炎是全球肝病的主要病因之一。慢性丙型肝炎可导致肝纤维化和肝硬化，进而发展为终末期肝病。抗病毒治疗可以清除病毒，阻止疾病进展，从而降低晚期肝病的发病率。本文旨在探讨抗病毒治疗，包括直接作用抗病毒药物，对伴有肝纤维化、代偿期和失代偿期肝硬化的慢性丙型肝炎患者的疗效和安全性。
